Antibiotics are among the most important medical advances of the last century. They have transformed once-life-threatening infections into treatable conditions and remain at the heart of modern healthcare.
However, their effectiveness is increasingly undermined by antibiotic resistance which is having serious real-world consequences, even in developed countries. Everyone is becoming aware of that, as it is publicized in newspapers regularly and general practitioner doctors are becoming more reluctant to prescribe antibiotics for unconfirmed infections.
As an example of this growing real-world problem, over the past decade the bacterial disease gonorrhea has developed resistance to nearly every class of antibiotics historically used to treat it.
By the late 2010s, health agencies in multiple countries reported cases of gonorrhea resistant to ceftriaxone, the last widely recommended first-line treatment. Some cases were effectively untreatable using standard regimens.
This is having serious global impact:
- Gonorrhea is a common infection, often asymptomatic
- Untreated or unsuccessfully treated infections can lead to infertility, pelvic inflammatory disease, and increased HIV transmission
- Resistant strains spread silently through communities
- Increased risk of prostate and cervical cancers
Public-health authorities described drug-resistant gonorrhea as a “superbug” threat, prompting emergency updates to treatment guidelines and intensified surveillance.
What it illustrates:
- Resistance can undermine even well-established treatment protocols
- Species identification alone is insufficient, specific resistant strains are causing the problem
- Surveillance and rapid detection are essential to slowing spread
This case is often cited as a warning that antibiotic resistance can turn routine infections into major clinical challenges. It is why our work in delivering precise analysis is so vital and will become even more so in the future.
Understanding Antibiotic Resistance
Antibiotic resistance occurs when bacteria develop the ability to survive exposure to drugs that are designed to kill them or stop their growth.
This resistance can be intrinsic, meaning certain bacteria are naturally unaffected by specific antibiotics, or acquired through abnormal genetic changes. These changes may occur through spontaneous mutations or by the transfer of resistance genes between bacteria.
Once resistance develops, previously effective treatments may no longer work, increasing the risk of prolonged illness, complications, and transmission.
A Growing Global Health Challenge
Antibiotic resistance is now recognized as a major global health concern by the World Health Organization and other major bodies.
Resistant infections are associated with higher rates of treatment failure, longer hospital stays, and increased healthcare costs. In some cases, resistance limits treatment options to older, harsher, or less effective drugs.
Beyond the impact on individual patients, antibiotic resistance poses broader public-health risks. Resistant bacteria can spread within hospitals, communities, and across borders, making local treatment decisions part of a global challenge.
The Clinical Reality: Treating Infections Under Time Pressure
In routine clinical practice, treatment decisions often need to be made quickly.
Traditional microbiological methods rely on growing bacteria in culture and then testing their susceptibility to antibiotics. While highly informative, these processes may take days to complete using standard lab procedures in most developed countries.
As a result, clinicians frequently prescribe antibiotics without full knowledge based on the most likely pathogens and local resistance patterns, mostly before laboratory confirmation is available.
This clinical reality has driven growing interest in diagnostic approaches that can provide earlier insight into both pathogen identity and likely antibiotic response, which could transform our ability to combat disease in the future.
While empiric therapy is often necessary, it carries inherent risks. The chosen antibiotic may not be effective against the infecting organism, or it may be broader than necessary, contributing to unnecessary selective pressure that encourages resistance. It is this problem our work seeks to eradicate.
Why Species Identification Alone Is Often Insufficient
Identifying the bacterial species responsible for an infection is an important step, but it is not always enough to guide optimal patient treatment
Different strains within the same species can vary dramatically in their resistance profiles. Two infections caused by the same bacterial species may respond very differently to the same antibiotic, depending on their genetic makeup.
Increasingly, strain and gene-level information is recognized as critical for understanding resistance patterns that are not visible through species identification alone.
Linking Pathogen Identity To Likely Treatment Response
Improving early treatment decisions depends on understanding not just what organism is present, but how it is likely to respond to therapy.
Additionally, this rapid testing and the harmlessly built into other types of testing regime, for example drug testing. This could aid faster, cheaper, and a more holistic approach to addressing both addiction and responses to illness and infection generated by it.
Going a step further, within the USA, workplace drug testing could also be used to harness this rapid dual approach, and even to spot problems within specific types of standard testing such as urine, hair, or blood.
Advances in molecular diagnostics and genomics make it possible to detect genetic signatures associated with resistance more rapidly than traditional methods. When combined with comprehensive reference data, these signatures can be used to estimate the likelihood that a given antibiotic will be effective on that individual.
Importantly, this approach is designed to support and not the place clinical judgment. Treatment guidance based on genomic information is probabilistic and must always be interpreted within the patient’s broader clinical context.
Antibiotics And Precision Medicine
Antibiotic stewardship seeks to ensure that patients receive the right antibiotic, at the right dose, for the right duration, something that is currently rarely achieved even in a privately managed setting rather than universal public healthcare.
More precise diagnostic information supports stewardship by reducing unnecessary exposure to broad-spectrum antibiotics and enabling targeted therapy when appropriate. This benefits individual patients while also helping to preserve the effectiveness of antibiotics for future use.
Precision medicine in infectious disease applies the same principle, namely, tailoring treatment based on detailed information about the infectious agent, rather than relying solely on population averages.
Such precision medicine first became well known during the pandemic, and rapid and tailored treatments have developed from it, including vaccinations and even personalized cancer treatments.
The Role Of Genomics And Data In Combating Resistance
Genomics has become an increasingly important tool in understanding how antibiotic resistance develops, spreads, and persists across healthcare and community settings.
At the molecular level, resistance is often driven by specific genetic changes, including the acquisition of resistance genes, mutations in drug targets, or mechanisms that alter drug transport and metabolism.
Genomic analysis makes it possible to detect these features directly, providing insight into resistance mechanisms that may not be apparent through standard testing.
Beyond individual cases, genomic data is particularly valuable when examined across large numbers of infections. Aggregating genetic information from many isolates allows patterns to emerge, revealing how specific resistance traits are associated with certain strains, environments, or clinical contexts, allowing individualized analysis and response on a global basis.
One of the key strengths of genomic approaches is their ability to support real-time visibility into the movement of resistant strains. When genomic data is linked with contextual information such as time, location, and clinical setting, it can help identify emerging clusters, transmission routes, and sources of infection.
Such a capability is increasingly important in hospitals and long-term care facilities, where early detection of resistant strains can inform infection control measures and reduce further spread.
Equally important is the role of centralized reference datasets that link genetic signatures with clinically observed resistance patterns. These datasets transform the raw information into data with a clinically meaningful context, allowing diagnostic tools to interpret new data against established knowledge.
Ultimately, genomics and data together offer a framework for moving from reactive responses to proactive resistance management. By integrating genetic insight with clinical, epidemiological, and general data, global health systems gain earlier awareness of emerging threats and a stronger evidentiary basis for treatment decisions and stewardship strategies.
While genomics alone cannot solve antibiotic resistance, it provides a powerful foundation for understanding its complexity and supporting more informed, coordinated efforts to preserve the effectiveness of existing and future antibiotics.
Looking Ahead: Improving First-Line Treatment Decisions
Addressing antibiotic resistance requires coordinated efforts across healthcare, laboratories, public health systems, and research.
If healthcare placed as much emphasis and use the same resources as, for example, private drug testing, then the industry and healthcare globally would be transformed. Where we spend huge amounts of money and effort detecting socially benign substances such as marijuana, we could be transforming infectious disease control instead.
Faster and more precise diagnostic insights can improve our confidence in early treatment decisions, reduce unnecessary antibiotic exposure, and help slow the spread of resistance. As diagnostic technologies continue to advance, integrating genomic insight into routine care has the potential to strengthen both individual patient outcomes and population-level health.
Antibiotic resistance is a complex problem, but improving how infections are identified and treated from the outset is a critical part of the solution – which we are proud to be at the forefront of.